New Alzheimer’s Treatments: Slow Memory Loss and Extend Independent Living

New Alzheimer’s Treatments

Alzheimer’s disease gradually impairs memory, thinking, and the ability to perform daily activities. For decades, available treatments could only address symptoms temporarily.

The recent FDA approval of new medications represents a significant development in Alzheimer’s care, as these are the first treatments designed to potentially slow disease progression by targeting one of its underlying biological causes.

These new medications slow cognitive decline by 27 to 35% compared to a placebo and extend independent living by 5 to 12 months for many study participants.

Understanding the Importance of Early Intervention Alzheimer’s is typically diagnosed in later stages, when symptoms have already significantly impacted daily life. However, researchers increasingly emphasize that the disease begins years, even decades, before outward signs appear. This pre-clinical phase, where amyloid accumulation and other brain changes are underway, is a critical window for intervention. Treatments that aim to slow decline are most effective when started early — making timely detection and diagnosis more important than ever.

The Science Behind the New Treatments

Researchers have identified two key abnormalities in Alzheimer’s-affected brains: amyloid plaques that form between brain cells and tau tangles that develop inside them.

The newly approved medications focus specifically on amyloid plaques – sticky protein deposits that accumulate years before symptoms appear. By helping to clear these plaques, the treatments aim to slow the disease’s progression rather than just manage its symptoms.

Currently Available Treatment Options

Leqembi (lecanemab), approved in 2023, was the first of these new-generation treatments to demonstrate clear clinical benefits. Administered through biweekly intravenous infusions, clinical trials showed it could slow cognitive decline by approximately 27% compared to placebo.

In practical terms, this translated to about 5–8 additional months of maintained cognitive abilities and independence for many participants. Treatment requires confirmation of amyloid presence through specialized testing and involves regular MRI monitoring due to potential side effects including brain swelling or bleeding.

Kisunla (donanemab), approved in 2024, works similarly but with monthly infusions. Trial data indicated a 35% slowing of decline, offering participants 7–12 more months before reaching the next disease stage.

A unique aspect of this treatment is the possibility of discontinuing infusions if amyloid levels drop sufficiently, though this requires careful medical supervision. Like Leqembi, it necessitates regular brain scans to monitor for potential side effects.

Aduhelm (aducanumab), while historically significant as the first amyloid-targeting treatment approved in 2021, has seen limited use due to less consistent clinical benefits and significant side effect risks.

Most specialists now consider the newer options to have more robust evidence supporting their use for appropriate candidates.

Preserve Cognitive Skills and Everyday Independence

These treatments may help preserve cognitive function and daily living abilities longer than previous options could.

The additional time gained varies by individual but often means several more months of managing personal care, making decisions, and engaging in familiar activities.

Importantly, these medications don’t reverse existing damage or stop the disease permanently – they aim to slow its progression, particularly in early stages.

The ability to preserve day-to-day function is especially meaningful for individuals and their families. Extended independence can delay the need for in-home support, reduce caregiver burden, and provide more time for patients to participate in meaningful routines and relationships. This added time may also enable individuals to plan for future care preferences, legal arrangements, or advanced directives while cognitive abilities remain intact.

Important Practical Considerations

Treatment requires commitment to regular clinic visits for infusions and follow-up scans. Patients must have confirmed early-stage Alzheimer’s with amyloid buildup to qualify.

While Medicare covers the newer options for eligible patients, individuals should verify their specific coverage details.

Potential side effects, though usually manageable with monitoring, require careful discussion with healthcare providers.

Next Steps for Those Seeking Information

Individuals interested in learning more about these options should consult with memory specialists who can provide detailed explanations tailored to specific situations.

Diagnosis confirmation, including amyloid testing, represents an essential first step before considering treatment.

Comprehensive discussions should weigh potential benefits against treatment demands and individual health circumstances.

Where Do Verbal Memory Exams Fit?

Before pursuing advanced Alzheimer’s treatments, patients must confirm early-stage cognitive decline and the presence of amyloid plaques. However, many individuals may experience memory changes long before they qualify for imaging or medication.

This is where Verbal Memory Exams play a vital role.

These scientifically validated, self-administered assessments can:

• Detect early cognitive changes, especially in verbal memory and fluency—areas often affected first in Alzheimer’s.
• Help identify who might benefit from further diagnostic evaluation, including amyloid testing or consultation with a memory specialist.
• Provide an accessible, at-home screening tool for those concerned about memory changes but not yet diagnosed.

Unlike amyloid PET scans or spinal taps, verbal memory exams offer a low-cost, no-risk starting point that empowers individuals to take early action.

By identifying subtle impairments earlier, these exams may help individuals:

• Monitor their cognitive health over time
• Decide when to seek more specialized care
• Begin lifestyle changes that may delay further decline

They also serve an important role in ongoing care. When tracked over time, verbal memory results can offer patients and clinicians an additional layer of data to monitor changes and evaluate the effectiveness of interventions. In a healthcare system where access to specialists and imaging may be limited, these exams provide an important first step in proactive brain health.

A Note on Continuing Research

The development of these treatments marks an important step forward, but research continues to refine their use and develop additional options.

Scientists are actively investigating treatments targeting other aspects of Alzheimer’s pathology, including tau tangles and inflammatory processes, which may lead to further advances in coming years.

Additionally, researchers are exploring the potential of blood-based biomarkers as a simpler and more accessible way to detect Alzheimer’s changes in the body. This area of study may ultimately make diagnosis faster and less invasive, complementing existing tools like memory exams and imaging. As science advances, combining multiple approaches — lifestyle, cognitive screening, and medical therapy — may offer the most effective path forward.

Disclaimer:This article is informational only. It does not constitute medical advice or recommendation. Treatment decisions should be made in consultation with qualified healthcare professionals who can evaluate individual circumstances.